AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company operates through two primary segments: BioPharmaceuticals and Oncology.
Founded in 1999 through the merger of the Sweden-based Astra AB and the UK-based Zeneca Group PLC, AstraZeneca is headquartered in Cambridge, United Kingdom.
Main Product(s):
AstraZeneca is known for its diverse portfolio in major disease areas including oncology, respiratory, cardiovascular, renal and metabolic diseases. The company has a significant presence in the development of treatments for various forms of cancer and other serious illnesses.
Short History of AstraZeneca PLC:
1999 – AstraZeneca was formed by the merger of Astra AB and Zeneca Group PLC.
Early 2000s – The company focused on developing new products in the areas of cardiovascular, respiratory, oncology, and neuroscience.
2010s – Emphasis shifted towards biologics in its research and development efforts.
2020-2021 – AstraZeneca was instrumental in developing one of the first COVID-19 vaccines during the global pandemic.
2023 – Continued focus on innovation in drug development, particularly in oncology and respiratory diseases.
Key Executives:
Name
Title
Pay
Exercised
Year Born
Mr. Pascal Soriot D.V.M., M.B.A.
CEO & Executive Director
5.98M
N/A
1959
Dr. Aradhana Sarin M.D.
CFO & Executive Director
3.42M
N/A
1975
Ms. Pam P. Cheng
EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board
N/A
N/A
1971
Mr. Andrew P. Barnett
Head of Investor Relations
N/A
N/A
N/A
Mr. Jeffrey Pott
CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board
N/A
N/A
N/A
Gonzalo Vina
Head of Global Media Relations
N/A
N/A
N/A
Dr. Menelas Pangalos Ph.D.
EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board
N/A
N/A
1967
Dr. Ruud Dobber Ph.D.
Executive Vice-President of BioPharmaceuticals Business Unit
N/A
N/A
N/A
Dr. Susan Mary Galbraith M.D., Ph.D.
Executive Vice President of Oncology Research & Development